Market Research Industry Reports

Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Sarepta Therapeutics Inc (Sarepta), is a biopharmaceutical company that focuses on the discovery and development of novel RNA-based therapeutics for the treatment of rare and neuromuscular diseases. The company develops drugs based on its proprietary, highly-differentiated and innovative platform technology, phosphorodiamidate morpholino oligomer (PMO) chemistries. It principally focuses on developing its disease-modifying pipeline of exon-skipping candidates targeting Duchenne Muscular Dystrophy (DMD). The company is also developing various drug candidates based on its proprietary RNA-based technology and unique PMO chemistry. The drug candidates include AVI-7288 for the treatment of the Marburg virus and radavirsen (formerly AVI-7100) for influenza. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
Partnerships 13
Sarepta Therapeutics Enters into Research Agreement with Duke University 13
Sarepta Therapeutics Enters into Research Agreement with Genethon 14
Sarepta Therapeutics Enters into Research Agreement with Nationwide Childrens Hospital 15
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 16
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 17
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 18
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 19
Licensing Agreements 20
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 20
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Childrens Hospital 22
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 23
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 24
Equity Offering 26
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 26
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 28
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 30
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 31
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 33
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 35
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 36
Sarepta Therapeutics Completes Private Placement Of Shares 38
Debt Offering 39
Sarepta Therapeutics Announces Exercise of Initial Purchasers Option for USD95 Million in Private Placement of Notes Due 2024 39
Asset Transactions 40
Sarepta Therapeutics to Sell its Pediatric Disease Priority Review Voucher 40
Sarepta Therapeutics Inc - Key Competitors 41
Sarepta Therapeutics Inc - Key Employees 42
Sarepta Therapeutics Inc - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Strategy And Business Planning 44
Jun 27, 2017: Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover 44
Financial Announcements 45
Mar 01, 2018: Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments 45
Oct 25, 2017: Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments 48
Jul 19, 2017: Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments 50
Apr 27, 2017: Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments 52
Feb 28, 2017: Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments 54
Corporate Communications 56
Dec 05, 2017: Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors 56
Sep 25, 2017: Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer 57
Apr 05, 2017: Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 58
Apr 03, 2017: Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer 59
Mar 30, 2017: Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Companys Strategic and Scientific Advisory Board 60
Government and Public Interest 61
Apr 10, 2018: Advocacy groups urge US government to lower price of costly DMD drug 61
Product News 62
09/06/2017: Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053) 62
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List Of Tables

List of Tables
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
Sarepta Therapeutics Enters into Research Agreement with Duke University 13
Sarepta Therapeutics Enters into Research Agreement with Genethon 14
Sarepta Therapeutics Enters into Research Agreement with Nationwide Childrens Hospital 15
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 16
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 17
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 18
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 19
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 20
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Childrens Hospital 22
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 23
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 24
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 26
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 28
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 30
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 31
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 33
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 35
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 36
Sarepta Therapeutics Completes Private Placement Of Shares 38
Sarepta Therapeutics Announces Exercise of Initial Purchasers Option for USD95 Million in Private Placement of Notes Due 2024 39
Sarepta Therapeutics to Sell its Pediatric Disease Priority Review Voucher 40
Sarepta Therapeutics Inc, Key Competitors 41
Sarepta Therapeutics Inc, Key Employees 42
Sarepta Therapeutics Inc, Other Locations 43
Sarepta Therapeutics Inc, Subsidiaries 43

List Of Figures

List of Figures
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its

USD 250View Report

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125View Report

Agile Therapeutics Inc (AGRX) - Medical Equipment - Deals and Alliances Profile

Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol

USD 250View Report

C3J Therapeutics Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

C3J Therapeutics Inc (C3J), formerly C3 Jian Inc is a clinical-stage biotechnology company that offers discovery and development of novel targeted antimicrobials, synthetic bacteriophage and antimicrobial peptides. Its pipeline products

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :64
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube